Sanofi Announces Decision Not to Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews

RegulatoryrejectedamlitelimabNegative

AI Analysis

Summary

Sanofi announced the discontinuation of amlitelimab, an OX40-ligand monoclonal antibody in clinical development for moderate-to-severe atopic dermatitis, and decided not to submit for global regulatory reviews.

Outcome Details

Sanofi announced discontinuation of clinical development and decision not to submit for global regulatory reviews

Importance:7/10

Sentiment:

-0.80

atopic dermatitisclinical development discontinuationregulatory decisionmonoclonal antibodyOX40-ligand

Related Companies

$SNY

Read the original article

Published by Drugs.com Clinical Trial Results on July 24, 2026 1:07 AM

Read Original